Introduction
The seminal discovery of a method to engineer human induced pluripotent stem cells (iPSCs) from terminally differentiated cells by Shinya Yamanaka's group [1] in 2007 paved the way for the development of iPSC-based models of human disease. For many years, stem cells have been recognized for their potential for regenerative therapies and as tools for deciphering the molecular pathways of disease. Although the use of embryonic stem cells (ESCs) is limited due to ethical and technical issues, iPSCs display properties of ESCs but are readily generated from patients. The broad utility of iPSCs is well illustrated in the study of genetic cardiovascular diseases, as the available human ESCs do not harbor the desired mutation, and relevant primary cells are difficult to obtain and propagate in culture (Table 1) . Additionally, as the concept of cardiac stem cell transplantation advances, avoiding the problem of host-donor immunological incompatibility is strongly advantageous.
Generation and characterization of induced pluripotent stem cell-derived cardiomyocytes
Technologies to generate iPSCs and differentiate them into a variety of cell types have become increasingly sophisticated and have enabled the derivation of iPSCderived cardiomyocytes with relatively high efficiencies.
Generation of induced pluripotent stem cells
Current iPSC technology is based on the overexpression of a cocktail of transcription factors that act as master regulators of pluripotency through the modification of epigenetic patterns and gene expression. The earliest experiments to generate iPSCs were performed by transducing somatic cells with retroviruses or lentiviruses [1, 2] , whereas newer methods such as inducible lentiviruses [3] , adenoviruses [4] , transposon-based systems [5] , small molecules [6] , and transfection of modified RNAs [7 ] have been employed to avoid genomic integration and increase the efficiency of iPSC generation.
The ESC-like colonies that emerge must demonstrate promoter demethylation and activation of endogenous stemness transcription factors such as OCT4 and NANOG, and expression of pluripotency markers such as surface antigens TRA1-81, TRA1-60, and SSEA4. The gold standard to verify pluripotency of human iPSCs is the ability to differentiate them into cells or tissues derived from each of the three germ cell layers in vitro and in vivo [8] .
Generation of induced pluripotent stem cell-derived cardiomyocytes
The ability to differentiate iPSCs into cardiomyocytes was advanced by the observation that three-dimensional ESC aggregates called embryoid bodies could mature into spontaneously contracting cells, which stained positive for cardiomyocyte-specific markers [9] . Since then, our knowledge about the mechanisms of early heart development and the undertaking of screens for small molecule enhancers of cardiogenesis have been applied to generate improved protocols, which increase the efficiency of producing iPSC-derived cardiomyocytes. Although earlier protocols relied on culturing embryoid bodies in media containing 20% fetal bovine serum [10] , the use of three families of extracellular growth factors required for cardiac development in mammals -the bone morphogenic proteins (BMPs), the WNT proteins, and the fibroblast growth factors (FGFs) -have been shown to enhance cardiomyocyte formation from embryoid bodies to 40-50% after incubation in culture over a variety of days [11 ] (Fig. 1 ). These growth factors can likely be used in synergy with small molecules such as ascorbic acid and sulfonyl hydrazones, which have been shown to increase in-vitro cardiogenesis from stem cell populations and to upregulate the expression of cardiac-specific genes [12 ] .
Purification of induced pluripotent stem cell-derived cardiomyocytes
Although the mixed cell population resulting from embryoid bodies is adequate for some studies, nearly pure cardiomyocytes are needed for other potential uses such as gene expression analyses. The lack of a reliable cardiomyocyte cell surface marker makes this purification challenging, but several methods have been developed that enable cardiomyocyte identification and isolation. The most promising are the transgenic selection methods, which currently involve lentiviral infection of iPSCs with fluorescent or antibiotic resistance selection genes under the control of cardiac gene-specific promoters, such as human myosin light chain-2v and a-myosin heavy chain (aMHC) (Fig. 1 ). These transgenic methods allow efficient in-vitro monitoring of cardiomyocyte generation and yield a purity of more than 90% [13, 14 ] . The isolation of pure iPSC-derived cardiomyocytes is essential for their characterization in vitro, although the development of efficient nonviral purification methods would be optimal, and required for potential future therapeutic use. This technology will also enable the future isolation of cardiac lineage and chamber-specific cell types, which will greatly enhance our capacity to investigate normal and abnormal cardiac development.
Characterization of induced pluripotent stem cellderived cardiomyocytes
The ability to use iPSC-derived cardiomyocytes for cellbased therapies or to investigate disease pathogenesis relies on the establishment of their similarity to functioning cardiomyocytes. Many studies have shown that cardiomyocytes generated from ESCs and iPSCs resemble immature fetal cardiomyocytes in their gene expression profile as well as their electrophysiological and structural properties. Gene expression analysis in a pure ESC-derived cardiomyocyte population demonstrated upregulation of cardiac-specific transcription factors and basic cardiac function genes, yet was accompanied by high levels of expression of several genes involved in cardiac differentiation not found in adult cardiomyocytes [15] . Ultrastructural examination of contracting ESC-derived embryoid bodies in culture revealed initial myofibril and sarcomere disorganization, with progressive evolution to a more organized structure and a concomitant increase in cell length and area. Importantly, these cells still lacked the development of the T tubule system after 60 days in culture, indicating a failure of complete maturation to an adult cardiomyocyte phenotype [16] . Similarly, investigation of ESCderived and iPSC-derived cardiomyocyte excitationcontraction coupling revealed immature calcium handling and a negative force-frequency relationship when stimulated [17, 18] . Despite these differences, studies have shown that iPSC-derived cardiomyocytes express functional Na þ , K þ , and L-type Ca 2þ channels, and respond to b-adrenergic stimulation [19] . The maturity level of these cells is a potential confounding factor in modeling certain disease phenotypes. Methods to enhance the maturity of these cells to an adult state are currently under investigation.
Using induced pluripotent stem cell-derived cardiomyocytes to study LEOPARD syndrome
The iPSC-derived cardiomyocytes were first shown to recapitulate a cardiac disease phenotype as a model for disorders of the RAS/MAPK signaling pathway.
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Figure 1 Generation and purification of induced pluripotent stem cell-derived cardiomyocytes
Successful derivation of purified iPSC-derived cardiomyocytes has been achieved through infection of iPSCs with a lentivirus encoding a selectable marker driven by a cardiomyocyte-specific promoter [14 ] . Exposure to a cocktail of cytokines over a defined time-course efficiently induces cardiogenesis. TGFb signaling, activated by BMP4 and Activin A, along with bFGF signaling, induces a population of cells expressing mesodermal markers. The addition of VEGF and DKK1, a selective inhibitor of the canonical WNT signaling pathway, further promotes cardiogenesis through induction of markers of cardiogenic mesoderm [11 ] . Cardiovascular precursors develop into a heterogeneous cell population including endothelial cells, fibroblasts, smooth muscle cells, and cardiomyocytes. Purification of cardiomyocytes is achieved through drug selection or cell sorting. bFGF, basic fibroblast growth factor; DKK1, Dickkopf-related protein 1; FACS, fluorescence-activated cell sorting; iPSC, induced pluripotent stem cell; ISL1, Islet1; VEGF, vascular endothelial growth factor.
RAS/MAPK genetic disorders and their clinical phenotypes
The 'RASopathies' are a family of autosomal dominant developmental disorders caused by mutations in the RAS/MAPK pathway, which generally result in increased signaling. The RAS/MAPK pathway is integral to many aspects of cell migration, proliferation, differentiation, and survival, and thus genetic mutations in this pathway result in developmental defects affecting multiple organ systems, one of the most prominent being the cardiovascular system. Cardiovascular abnormalities are common in many RASopathies, including Noonan syndrome and its related disorder LEOPARD syndrome. Pulmonic stenosis is seen in 23% of patients with LEOPARD syndrome, and more than 50% of patients with Noonan syndrome, whereas hypertrophic cardiomyopathy (HCM) is observed in up to 80% of patients with LEOPARD syndrome compared with about 20% of patients with Noonan syndrome [20, 21] .
The most commonly occurring mutations causing Noonan syndrome and LEOPARD syndrome occur in PTPN11, which encodes the Src homology-2 (SH2) domain-containing nontransmembrane protein tyrosine phosphatase SHP2. Heterozygous missense mutations in PTPN11 are observed in about 50% of Noonan syndrome cases and up to 90% of LEOPARD syndrome cases [22, 23] . Noonan syndrome-associated PTPN11 mutations result in a gain-of-function phenotype [22, 24] , whereas LEOPARD syndrome-associated PTPN11 mutations have mixed gain-of-function and dominantnegative effects [25, 26] . Despite their varying molecular effects, mutations causing Noonan syndrome and LEOPARD syndrome result in a very similar spectrum of clinical phenotypes. This phenomenon necessitates further investigation into the complex involvement of SHP2 in cell processes such as proliferation, migration, and differentiation, and its role in a wide variety of signaling events such as receptor tyrosine kinase, cytokine, and integrin-evoked extracellular-signal-regulated kinase (ERK) activation. Understanding how altered RAS pathway signaling engenders cardiac hypertrophy and the characterization of Noonan syndrome-associated and LEOPARD syndrome-associated hypertrophy is of great clinical importance.
Modeling LEOPARD syndrome-associated cardiac hypertrophy
Carvajal-Vergara et al. [27 ] generated iPSCs from dermal fibroblasts derived from two LEOPARD syndrome patients harboring the T468M substitution in PTPN11 using recombinant retroviruses encoding OCT4, SOX2, KLF4, and MYC. After exposure of iPSCs to a defined set of growth factors over a series of days, cardiac troponin T (cTNT) expression was detected in spontaneously beating embryoid bodies. The LEOPARD syndrome-derived cardiomyocytes displayed increased median cell surface area and sarcomeric organization compared with wild type (WT)-derived cardiomyocytes, consistent with a hypertrophic response. The authors also investigated the status of nuclear factor of activated T-cells (NFAT)c4 localization, as dephosphorylation of NFAT transcription factors by active calcineurin and subsequent NFAT nuclear localization has been implicated in the pathogenesis of cardiac hypertrophy. A higher proportion of LEOPARD syndrome cardiomyocytes displayed NFATc4 nuclear localization compared with WT, possibly implicating the calcineurin-NFAT pathway in the pathogenesis of LEOPARD syndrome hypertrophy. The LEOPARD syndrome iPSCs also had an increased abundance or phosphorylation of various signaling receptors and kinases, including EGFR, MEK1, and ERK1/2, consistent with increased activation of the RAS/MAPK pathway. bFGF-evoked ERK1/2 activation, however, was not observed in LEOPARD syndrome iPSCs. This study was the first to create a human iPSC-derived cardiomyocyte disease model, recapitulating a hypertrophic phenotype and altered RAS/MAPK signaling. This model validated the use of iPSC-derived cells to study the cardiac effects of human genetic disorders, an important advance as these iPSC-derived cardiomyocytes closely mimic the human disease state and are efficient laboratory tools (Table 1) . Additionally, the ability to differentiate mutant iPSCs into a multitude of cell types enables investigation into the diverse manifestations of genetic syndromes.
Using induced pluripotent stem cell-derived cardiomyocytes to study long-QT syndrome
The iPSC-derived cardiomyocytes have also recently been used to further understand the mechanisms underlying long-QT syndrome (LQTS). This work is important not only in advancing our knowledge about the pathogenesis of LQTS, but also in laying the groundwork for the future use of iPSC-derived cardiomyocytes in electrophysiological studies, an important area of investigation of drug safety and pharmacological effects.
Long-QT syndrome
LQTS is a congenital cardiovascular disorder characterized by a prolonged QT interval, recurring syncopal episodes, and a tendency toward polymorphic ventricular tachycardia leading to sudden cardiac death [28] . Autosomal dominant mutations in several genes encoding cardiac ion channels have been identified as causative for this disorder, with the majority of cases due to mutations in KCNQ1, KCNH2, and SCN5A. These genes respectively encode the alpha subunits of the delayed rectifier potassium channel conducting the I KS (slow) current, the I KR (rapid) current, and the cardiac sodium channel. Mutations in KCNQ1 are estimated to cause about 50% of LQTS cases and underlie LQTS type 1 (LQT1), whereas mutations in KCNH2 cause about 40% of LQTS cases and underlie LQTS type 2 (LQT2). Although it is widely accepted that KCNQ1 and KCNH2 mutations cause a reduction in their respective potassium currents, this has not yet been demonstrated in human cardiomyocytes, which have ion channel expression and electrophysiological properties that are distinct from animals typically used for disease modeling.
Modeling long-QT syndrome
Moretti et al.
[29 ] generated iPSCs from skin fibroblasts derived from two family members with the autosomal dominant missense mutation R190Q in KCNQ1 using retroviruses encoding the transcription factors OCT3/4, SOX2, KLF4, and c-MYC. The iPSCs were subsequently differentiated into cardiomyocytes in differentiation media consisting of 20% fetal calf serum. Three distinct single-cell action potentials were generated resembling fetal atrial, ventricular, or nodal cardiomyocytes. The authors found that atrial and ventricular cardiomyocytes with the LQT1 mutation displayed prolonged action potentials with decreased repolarization velocities, as well as decreased action potential duration (APD) shortening in response to higher pacing frequencies compared with control cardiomyocytes. In controls, KCNQ1 was localized to the cell membrane as expected, whereas mutant KCNQ1 was intracellular and colocalized with the endoplasmic reticulum marker disulfide isomerase, a novel finding. In cotransfection experiments, the extent of WT KCNQ1 cell membrane localization was found to be dependent upon the amount of mutant KCNQ1 present, suggesting a dominant negative effect.
Electrophysiological analysis of the I K current combined with I KS -specific or I KR -specific channel inhibitors revealed a specific reduction in I KS in patient-derived cardiomyocytes. Additionally, the I KS current in patientderived cardiomyocytes required higher voltages for activation, displayed delayed rates of deactivation, and was unresponsive to adrenergic stimulation. Consistent with altered I KS function, isoproterenol exposure resulted in a positive chronotropic effect with a shortened APD in control cardiomyocytes, whereas the mutant cells paradoxically displayed an increased APD with some cardiomyocytes developing early afterdepolarizations (EADs), illustrating their potential for arrhythmic activity. Importantly, these effects on patient-derived cardiomyocytes were mitigated by pretreatment with propranolol, a nonselective beta-blocker, which is clinically efficacious for LQT1.
A more recent publication by Itzhaki et al.
[30 ] addressed the effects of the A614V missense mutation in KCNH2 in iPSC-derived cardiomyocytes from patients with LQT2. Similarly to Moretti et al., the authors were able to recapitulate a prolonged APD in both atrial and ventricular cardiomyocytes along with delayed repolarization velocities. The use of an I KR -specific inhibitor allowed the validation of a specific reduction in the I KR current in LQT2-derived cardiomyocytes. In both singlecell analysis and microelectrode array mapping on multicellular clusters of cardiomyocytes, an increased incidence of EADs and subsequent premature beats was observed in the LQT2-derived cardiomyocytes. This disease phenotype was exploited to identify potentially corrective drugs not currently used clinically for LQTS. The authors found that the Ca 2þ channel blocker, nifedipine, and the K ATP channel opener, pinacidil, significantly reduced the APD in LQT2-derived cardiomyocytes, while completely eliminating all EADs and premature beats in single cells and multicellular clusters. The late Na þ channel blocker, ranolazine, did not have an effect on ADP, yet still reduced EADs in LQT2-derived cardiomyocytes.
The studies by Moretti et al. and Itzhaki et al. recapitulated the electrophysiological characteristics of LQTS in iPSC-derived cardiomyocytes and provided insights into its pathogenesis. Notably, both LQT1 patients used in the LQT1 study were asymptomatic at the time of skin biopsy, yet cardiomyocytes derived from these patients displayed molecular manifestations of the disease in vitro that could be therapeutically modulated. Species-dependent differences in cardiac ion channel expression and global genetic regulation provide the rationale for the use of human cardiomyocytes that can be pharmacologically manipulated to study cardiac disease mechanisms and identify novel therapeutics.
Future directions and conclusion
In the study of both LEOPARD syndrome and LQTS, iPSC-derived cardiomyocytes have recapitulated the clinical disease phenotype in vitro. They are able to be therapeutically modulated and are a platform for the discovery of novel mechanisms of pathogenesis. The future of iPSC technology provides promising and exciting avenues for further elucidating the pathogenesis of complex disorders, developing cell-based therapies, and identifying novel therapeutic compounds.
Transdifferentiation of fibroblasts into cardiomyocytes
The process of creating iPSCs and their subsequent differentiation into cardiomyocytes is time-consuming and subjects the cells to multiple rounds of manipulation. Recently, Ieda et al. [31 ] demonstrated for the first time the ability to differentiate mouse cardiac and dermal fibroblasts directly into cardiomyocytes. The authors used the viral transduction of a combination of three transcription factors (Gata4, Mef2c, and Tbx5), selected for their known central roles in early heart development, to induce differentiation. The derived cardiomyocytes expressed cardiac-specific markers, spontaneously contracted in culture, and displayed a gene expression pattern similar to neonatal mouse cardiomyocytes. Injecting cardiac fibroblasts into mouse hearts just 1 day after viral transduction led to in-vivo differentiation into cardiomyocytes expressing a-actinin and aMHC. Another recent paper reported the successful generation of cardiomyocytes directly from mouse embryonic fibroblasts in vitro through the short-term overexpression of pluripotency factors followed by exposure to cardiogenic cytokines [32 ] . It remains to be seen if transdifferentiation of fibroblasts directly into cardiomyocytes can occur in human cells, but this work lays the foundation for more efficient generation of cardiomyocytes with a decreased potential for tumor formation, and the possibility of reprogramming cells in vivo.
Identifying cardiac progenitor populations
Successful cardiac cell transplantation is dependent upon cell survival and proliferation in vivo, and the absence of tumor formation or an immunological response. The identification of a human cardiac progenitor cell population capable of giving rise to all three major cardiovascular lineages (cardiomyocytes, endothelial cells, smooth muscle cells) would be a major advance for the field of cardiac regeneration. Yang et al. [11 ] identified an FLK1 low , C-KIT neg population derived from human ESCs that was able to differentiate into all three cardiovascular lineages in vitro and after transplantation, without evidence of teratoma formation. Another human ESC-derived progenitor population expressing ISL1 was identified by Bu et al. [33 ] and has subsequently been derived from human iPSCs and been shown to repopulate the three cardiovascular lineages in vitro [34 ] . iPSCs are a uniquely useful tool for the identification of progenitor populations, as analysis and manipulation along developmental timelines are possible, and provide a platform for autologous cardiac cell transplantation in the future.
Using induced pluripotent stem cell-derived cardiomyocytes for drug screening Finally, the use of iPSC-derived cardiomyocytes for drug screening is an exceedingly valuable application for this technology, but investigation into whether these cells respond to drugs similarly to ESC-derived and adult cardiomyocytes is essential before this can become a reality. Yokoo et al. [35 ] compared the effects of an array of cardioactive compounds on human iPSC-derived and ESC-derived cardiomyocytes. The drugs elicited similar responses in both cell populations in beating frequency and contractility measurements and mirrored their clinically observed effects. A larger number of compounds have been tested in ESC-derived cardiomyocytes, with most eliciting the expected responses but some producing no observable effect [36 ] . It has been shown that, as iPSC-derived and ESC-derived cardiomyocytes mature in culture, their protein expression, structural organization, and ion channel functioning mature as well. Therefore, it is important to consider the phenotype of these derived cardiomyocytes as well as the appropriate therapeutic doses when undertaking a drug screen.
In sum, the applications for iPSC-derived cardiomyocytes are vast and provide us with the ability to enhance greatly our understanding of disease processes, as well as provide improved genotype-specific therapeutics to our patients. 
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